June 8, 2017 / 12:26 PM / 4 months ago

BRIEF-Sophiris Bio says first patient has been dosed in phase 2b study of topsalysin

June 8 (Reuters) - Sophiris Bio Inc

* Sophiris Bio announces that the first patient has been dosed in phase 2b study of topsalysin in patients with clinically significant localized prostate cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below